Myricx Pharma, a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases in cancer, unveiled an initial £4.5 million in seed financing from experienced venture investors, Sofinnova Partners and Brandon Capital Partners.
November 16, 2020
· 7 min read